Clinical Course and Factors Correlated with Severe Morbidity and Mortality in Patients with Coronavirus Disease 2019 Undergoing Maintenance Dialysis in Kanagawa, Japan
Objective Patients undergoing maintenance dialysis are at a higher risk of morbidity and mortality due to severe coronavirus disease 2019 (COVID-19) than the general population. However, longitudinal data regarding this subpopulation of patients are lacking. We therefore examined the prognosis of patients with COVID-19 undergoing maintenance dialysis between 2020 and 2023. In addition, we explored the factors correlated with COVID-19 severity, focusing on the transition thereof throughout the observational period. Methods The primary outcome was the progression to severe or fatal COVID-19. We evaluated the correlation between the primary outcome and baseline demographic and clinical characteristics of patients. Patients undergoing maintenance dialysis who were hospitalized for mild-to-moderate COVID-19 between February 2020 and April 2023 were enrolled at four institutions in Kanagawa, Japan. Results Of the 173 patients, 7 (4.0%) developed severe COVID-19, and 12 (6.9%) died. The severe/death cohort was significantly older, with a higher percentage of unvaccinated patients than the non-severe cohort (58.2% and 25.0%, respectively; p=0.016). Thymus and activation-regulated chemokine levels on admission were lower in the severe/death cohort than in the non-severe cohort, albeit not to a statistically significant degree (148±84 mg/dL and 342±657 pg/mL, respectively; p=0.082). A multivariate logistic regression analysis revealed that the odds ratio for severe morbidity or death was 0.23 (95% confidence interval: 0.07-0.75) for vaccinated patients. Conclusion In patients undergoing maintenance dialysis, the severity rate of COVID-19 is approximately 10%. Vaccination was correlated with a reduced risk of severe COVID-19.
Authors
- Machiko Yabana
- Hiroshi Mitsuhashi
- Masaaki Hanaoka (ORCID: https://orcid.org/0000-0001-6270-1302)
- Yoshiyuki Toya
- Ryu Kobayashi (ORCID: https://orcid.org/0009-0009-4748-5352)
- Jin Oshikawa
- Kohei Ishiga (ORCID: https://orcid.org/0000-0002-9748-5811)
- Kengo Azushima (ORCID: https://orcid.org/0000-0002-5136-0730)
- Daisuke Kanai
- Tomohiko Kanaoka (ORCID: https://orcid.org/0000-0001-5267-3790)
- Tatsuya Haze (ORCID: https://orcid.org/0000-0001-8207-7025)
- Takehisa Iwano
- Kouichi Tamura (ORCID: https://orcid.org/0000-0002-0660-5372)
- Naohito Okami
- Toshiharu Kokuho
- Sho Kinguchi (ORCID: https://orcid.org/0009-0007-0952-8548)
- Yukiko Yamada
- Hiromichi Wakui
- Kohji Ohki
- Masashi Sakai
Institutions
- Fujisawa City Hospital (JP)
- Hiratsuka City Hospital (JP)
- Yokohama Minami Kyosai Hospital (JP)
- Yokohama City University Hospital (JP)
- Yokohama Sakae Kyosai Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2024-09-26
- DOI
- https://doi.org/10.2169/internalmedicine.4199-24
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Japan Agency for Medical Research and Development
- Boehringer Ingelheim Japan
- Japanese Association of Dialysis Physicians
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency